Your correct - I think in the long run, using various drugs to alter lipids, will probably turn out to be at best poor medical practice. There may be exceptions to the rule - i.e. genetic disorders. I think the FDA is starting to get the picture. Recently they decide lowering LDL-C is not good enough for approval. They want to see outcomes and sure enough these trials have shown at best modest results. So little chance these new drugs ever get approved. Now if Vascepa shows well over 15% reduction in events. We take the market in the add-in to Statin treatment and beyond.
News 
Market Data 
Discover 
